Effect of Prostacyclin on Haemostasis in Abdominal Surgery

The Effect of Prostacyclin on Haemostasis as Evaluated by Thrombelastography and Endothelial Markers in Patients Undergoing Major Abdominal Surgery. A Pilot Study

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01528943

Enrollment

Registered

2012-02-08

Start date

2012-03-31

Completion date

2014-01-31

Last updated

2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

prostacycline, endothel integrity and abdominal surgery

Brief summary

The purpose of this study is to investigate the effect of continuous perioperative infusion of prostacyclin on haemostasis and endothelial functionality in patients undergoing major abdominal surgery.

Interventions

DRUGProstacycline

Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min

DRUGIsotonic saline

same volume as the group that are allocated to prostacycline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and women above 18 years old * Undergoing Whipple surgery or liver resection * Able and willing to give informed consent

Exclusion criteria

1. Allergy towards the study medication 2. In treatment with platelet ADP receptor inhibitors or heparin (not including thrombosis prophylaxis), Factor Xa inhibitors, trombininhibitors, Vitamin K antagonists 3. Autoimmune disease 4. Intracranial bleeding within the last 6 months 5. Acute coronary syndrome or myocardial infarction within the last 6 months 6. Congestive heart disease 7. Pregnant or breastfeeding 8. Participating in another clinical study within the last 30 days 9. Liver cirrhosis 10. Need for renal replacement therapy

Design outcomes

Primary

Measure	Time frame
Change in endothelial biomarkers	Baseline to 6 hours postoperatively

Secondary

Measure	Time frame
Functional haemostasis evaluated by thrombelastography	Baseline to 6 hours postoperatively

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026